Ligand-induced large-scale chromatin dynamics as a biosensor for the detection of estrogen receptor subtype selective ligands

Gene

Volumn 458, Issue 1-2, 2010, Pages 37-44

  García Becerra, Rocio ^a   Berno, Valeria ^b   Ordaz Rosado, David ^a   Sharp, Zelton D ^c   Cooney, Austin J ^b   Mancini, Michael A ^b   Larrea, Fernando ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Chromatin; Estrogen receptor subtypes; Ligand selectivity; Synthetic progestins; Transcription

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GREEN FLUORESCENT PROTEIN; NANDROLONE DERIVATIVE; RNA POLYMERASE II; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; TRANSCRIPTION FACTOR; YELLOW FLUORESCENT PROTEIN;

ARTICLE; BIOSENSOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ESTROGEN ACTIVITY; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BIOSENSING TECHNIQUES; CHROMATIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HELA CELLS; HUMANS; LIGANDS; NANDROLONE; NUCLEAR RECEPTOR COACTIVATOR 1; RECEPTORS, ESTROGEN; TRANSCRIPTION, GENETIC;

MAMMALIA;

EID: 77952550322     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2010.03.007     Document Type: Article

References (42)

1. Amazit L., et al. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol. Cell. Biol. 2007, 27:6913-6932.
2. Andersen B., Rosenfeld M.G. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr. Rev. 2001, 22:2-35.
3. Beato M., Chavez S., Truss M. Transcriptional regulation by steroid hormones. Steroids 1996, 61:240-251.
4. Beekman J.M., Allan G.F., Tsai S.Y., Tsai M.J., O'Malley B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 1993, 7:1266-1274.
5. Berno V., Hinojos C.A., Amazit L., Szafran A.T., Mancini M.A. High-resolution, high-throughput microscopy analyses of nuclear receptor and coregulator function. Methods Enzymol. 2006, 414:188-210.
6. Berno V., et al. Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription. PLoS ONE 2008, 3:e2286.
7. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141:3657-3667.
8. Brzozowski A.M., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
9. Carson-Jurica M.A., Schrader W.T., O'Malley B.W. Steroid receptor family: structure and functions. Endocr. Rev. 1990, 11:201-220.
10. Chavez B.A., Vilchis F., Perez A.E., Garcia G.A., Grillasca I., Perez-Palacios G. Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites. J. Steroid Biochem. 1985, 22:121-126.
11. Couse J.F., Lindzey J., Grandien K., Gustafsson J.A., Korach K.S. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997, 138:4613-4621.
12. Day R.N., Maurer R.A. The distal enhancer region of the rat prolactin gene contains elements conferring response to multiple hormones. Mol. Endocrinol. 1989, 3:3-9.
13. Day R.N., Koike S., Sakai M., Muramatsu M., Maurer R.A. Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene. Mol. Endocrinol. 1990, 4:1964-1971.
14. Ekena K., Weis K.E., Katzenellenbogen J.A., Katzenellenbogen B.S. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J. Biol. Chem. 1997, 272:5069-5075.
15. Fritsch M., et al. A ligand-induced conformational change in the estrogen receptor is localized in the steroid binding domain. Biochemistry 1992, 31:5303-5311.
16. Garcia-Becerra R., et al. The intrinsic transcriptional estrogenic activity of a non-phenolic derivative of levonorgestrel is mediated via the estrogen receptor-alpha. J. Steroid Biochem. Mol. Biol. 2002, 82:333-341.
17. Garcia-Becerra R., et al. Synthetic 19-nortestosterone derivatives as estrogen receptor alpha subtype-selective ligands induce similar receptor conformational changes and steroid receptor coactivator recruitment than natural estrogens. J. Steroid Biochem. Mol. Biol. 2006, 99:108-114.
18. Harris H.A., Katzenellenbogen J.A., Katzenellenbogen B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002, 143:4172-4177.
19. Katzenellenbogen J.A., Katzenellenbogen B.S. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem. Biol. 1996, 3:529-536.
20. Kubli-Garfias C., Vazquez R., Cooney A.J., Larrea F. Ab initio electronic structure of the progestogen norethisterone and its 5 alpha-derivatives. J. Steroid Biochem. Mol. Biol. 2002, 82:385-391.
21. Kuiper G.G., Gustafsson J.A. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997, 410:87-90.
22. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5925-5930.
23. Kuiper G.G., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
24. Larrea F., Vilchis F., Chavez B., Perez A.E., Garza-Flores J., Perez-Palacios G. The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J. Steroid Biochem. 1987, 27:657-663.
25. Larrea F., et al. A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha. Endocrinology 2001, 142:3791-3799.
26. Lemus A.E., et al. Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. J. Steroid Biochem. Mol. Biol. 1992, 41:881-890.
27. Lemus A.E., et al. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J. Endocrinol. 2000, 165:693-702.
28. Matthews J., Celius T., Halgren R., Zacharewski T. Differential estrogen receptor binding of estrogenic substances: a species comparison. J. Steroid Biochem. Mol. Biol. 2000, 74:223-234.
29. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20:321-344.
30. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
31. Muddana S.S., Peterson B.R. Fluorescent cellular sensors of steroid receptor ligands. Chembiochem 2003, 4:848-855.
32. Norman B.H., et al. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J. Med. Chem. 2006, 49:6155-6157.
33. Pike A.C., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18:4608-4618.
34. Sharp Z.D., et al. Estrogen-receptor-alpha exchange and chromatin dynamics are ligand- and domain-dependent. J. Cell Sci. 2006, 119:4101-4116.
35. Stauffer S.R., et al. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 2000, 43:4934-4947.
36. Stauffer S.R., Huang Y., Coletta C.J., Tedesco R., Katzenellenbogen J.A. Estrogen pyrazoles: defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. Bioorg. Med. Chem. 2001, 9:141-150.
37. Stenoien D.L., Mancini M.G., Patel K., Allegretto E.A., Smith C.L., Mancini M.A. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. Mol. Endocrinol. 2000, 14:518-534.
38. Sun J., Meyers M.J., Fink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 1999, 140:800-804.
39. Ullrich J.W., Unwalla R.J., Singhaus R.R., Harris H.A., Mewshaw R.E. Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1, 3-diones. Bioorg. Med. Chem. Lett. 2007, 17:118-122.
40. Vilchis F., Chavez B., Perez A.E., Garcia G.A., Angeles A., Perez-Palacios G. Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progestin receptors. J. Steroid Biochem. 1986, 24:525-531.
41. Zhu B.T., Han G.Z., Shim J.Y., Wen Y., Jiang X.R. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006, 147:4132-4150.
42. Zwart W., et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J. 2007, 26:3534-3544.